More articles from Oncology: Clinical Therapy and Diagnosis

You have access
Evaluation of primary breast tumors using dedicated breast PET and whole body PET
Ella Jones, Deep Hathi, Wen Li, Youngho Seo, Robert Flavell, Benjamin Franc, Bonnie Joe, Laura Esserman and Nola Hylton

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 610;
You have access
Selective high dose Y-90 Theraspheres treatment of malignant liver lesions
Isis Gayed, Allan Cohen, Harleen Kaur and Ahmed Abdel Aal

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 632;
You have access
The F18 FDG PET in breast carcinoma: Do patient characteristics, tumor histology or receptor status, have any impact on final staging?
Yaser Baghdadi, Ana Valdivia and Charito Love

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 605;
You have access
Visceral fat metabolic activity evaluated by preoperative ¹⁸F-FDG PET/CT is independently associated with axillary lymph node metastasis in postmenopausal luminal breast cancer
Kisoo Pahk, Hyun Woo Kwon, Jae Seon Eo and Sungeun Kim

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 608;
You have access
Comparison of serum NEDD 9, CA 15-3 and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT
ESRA ARSLAN, Hale Aral, Tamer Aksoy, Cigdem Usul Afsar, Senem Karabulut, Fadime Can Trabulus, Riza Gursu and Tevfik Cermik

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 613;
You have access
Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: Feasibility, Biodistribution and Preliminary Dosimetry in a First-in-human study
Richard Baum, Maythinee Chantadisai, Christiane Smerling, Christiane Schuchardt, AVIRAL SINGH, Alexander Eismant, Frankis Almaguel, Dirk Mueller, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke and Harshad Kulkarni

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 633;
You have access
Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen
Youngho Seo, Yoonsuk Huh, Vishnu Murthy, Hillarie Windish, Beatrice Langton-Webster, Joseph Blecha, Henry VanBrocklin, Spencer Behr and Rahul Aggarwal

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 590;
You have access
PSMA-ligand uptake in posttherapeutic ¹⁷⁷Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC
Rudolf Werner, Johannes Thiele, Tobias Ross, Frank Bengel and Thorsten Derlin

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 595;
You have access
Prediction of Liver Function after Radioembolization Using the ¹³C-Methacetin Breath Test (MBT)
Malte Kircher

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 629;
You have access
First clinical results for radioligand therapy using the alpha emitter Ac-225-PSMA I&T in patients with end stage mCRPC
Mathias Zacherl, Franz Josef Gildehaus, Astrid Gosewisch, Guido Boening, Peter Bartenstein, Andrei Todica and Harun Ilhan

Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 592;

Main menu

User menu

Search

More articles from Oncology: Clinical Therapy and Diagnosis

Pages